USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: H. G. Pars Pharmaceutical Labo
City: Cambridge
State: MA
Zip+4: 02138
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $200,000.00 4

Award List:

H.

Award Year / Program / Phase: 1985 / SBIR / Phase I
Agency: HHS
Principal Investigator: Harry g. pars , PRINCIPAL INVESTIGATOR
Award Amount: $50,000.00
Abstract:
H. g. pars pharmaceutical laboratories' long-term goal is to develop and market an orally active antihypertensive drug from its series of sulfur and nitrogen cannabinoid analogs. hypotensive cannabinoids are believed to exert their effects by altering central sympathetic nervous system activity but… More

THE MODIFICATION OF -LACTAM ANTIBIOTICS CONTINUES TO BE A PROMISING MEANS FOR THE IMPROVEMENT OF THIS VERY IMPORTANT CLASS OF ANTIMICROBIALS.

Award Year / Program / Phase: 1985 / SBIR / Phase I
Agency: HHS
Principal Investigator: Eric p. duffy , PRINCIPAL INVESTIGATOR
Award Amount: $50,000.00
Abstract:
The modification of -lactam antibiotics continues to be a promising means for the improvement of this very important class of antimicrobials. the varied useful attributes of the new oxacephalosporin moxalactam, namely broad spectrum of activity, favorable pharmacokinetic profile, and stability,… More

CURRENT BACTERIOCIDAL AND FUNGICIDAL AGENTS ARE UNSATISFACTORY FOR USE ON SENSITIVE SOFT TISSUE OR MUCOUS MEMBRANE.

Award Year / Program / Phase: 1985 / SBIR / Phase I
Agency: HHS
Principal Investigator: Peter meltzer , PRINCIPAL INVESTIGATOR
Award Amount: $50,000.00
Abstract:
Current bacteriocidal and fungicidal agents are unsatisfactory for use on sensitive soft tissue or mucous membrane. there is no known chemical agent which possesses broad-range bacteriocidal and fungicidal activity and is nonirritant towards ocular tissue. the discovery of such an agent would be… More

AN EFFECTIVE ORAL MALE ANTIFERTILITY AGENT, WHICH IS BOTH NONTOXIC AND REVERSIBLE, IS NOT CURRENTLY AVAILABLE.

Award Year / Program / Phase: 1985 / SBIR / Phase I
Agency: HHS
Principal Investigator: Harry g. pars , PRINCIPAL INVESTIGATOR
Award Amount: $50,000.00
Abstract:
An effective oral male antifertility agent, which is both nontoxic and reversible, is not currently available. gossypol, the most promising nonsteroidal male antifertility lead, has an unacceptably narrow therapeutic ratio. we propose that the therapeutic ratio may be improved by alteration of the… More